Key facts
- Daraxonrasib nearly doubled median survival time for advanced pancreatic cancer patients in a trial.
- Patients on daraxonrasib lived a median of 13.2 months, compared to 6.7 months for chemotherapy recipients.
- The drug targets a mutated protein found in over 90% of pancreatic cancer cases.
- Side effects included rash and mouth sores, but quality of life improved for patients on daraxonrasib.
- Researchers plan to investigate earlier use of daraxonrasib and potential use before surgery.
Pancreatic cancer is one of the deadliest forms of cancer with historically low survival rates. The development of new treatments that can significantly extend patient survival and improve quality of life is a critical area of medical research and patient hope.